Haleon Pakistan was one of the first pharmaceutical companies in the USA to voluntarily disclose information about our work with physicians, including fees for speaking and consulting, which we have posted publicly since 2009. In 2010, we began disclosing payments to institutions and lead investigators for assisting with clinical research studies.

We publish the Physician Payments Report to detail our payments and other transfers of value to those US Health Care Professionals (HCPs) who  we have engaged as speakers about our medicines and the conditions they are approved to treat.

These speaking events are attended by other physicians. We also detail payments to physicians who work with us as advisors to help us understand trends in the delivery of healthcare and the evolving needs of patients and providers for more effective medicines and vaccines. We report payments for reasonable expenses incurred by physician speakers and advisers while conducting programmes on our behalf, such as meals, airfare and lodging. We also report modest meals provided to physicians who attend a speaker programme or in-office presentation, and other expenses which are non-cash items of value or services, such as certain educational items.

We currently disclose information about payments we make to HCPs in a number of European countries including the UK, France, Netherlands and Slovakia.

In line with new guidance from the European Federation of Pharmaceutical Industry Association (EFPIA), we will start to disclose certain payments to doctors across 33 European countries from January 2016 for payments made during 2015.  

This covers sponsoring individual HCPs to attend congresses and payments for speaking fees. Full details of the EFPIA Disclosure Code are available on the EFPIA website.

Outside of Europe and the USA, we continue to support and work towards transparency as industry associations or governments establish specific guidelines for disclosure.

We also continue to work towards publishing global figures at an aggregate level for the payments to HCPs that will continue, for activities such as advisory services and clinical research.